Meera Mohan, MD
Articles
Bispecifics in R/R MM: Selecting the Best Bispecific and Optimal Sequencing Strategies
Dr Mohan asks Dr Nadeem about the selection process among bispecific antibodies, the factors influencing decision-making, and the use of talquetamab, teclistamab, or elranatamab in specific patient subgroups, followed by a discussion with Dr Mann on next therapeutic steps if a patient experiences disease progression on talquetamab.
Implications of Talquetamab on the Current Treatment Landscape for R/R MM
Dr Mohan and Dr Mann discuss the current therapeutic landscape for relapsed/refractory multiple myeloma (R/R MM), alternative treatment strategies, and the real-world performance, advantages, and challenges of incorporating talquetamab into treatment protocols.
MonumenTAL: Key Efficacy Outcomes
Dr Nadeem to summarize the clinical evidence supporting talquetamab use in relapsed/refractory multiple myeloma, including key efficacy outcomes from the monumenTAL trials.
68-year-old male construction worker with a long history of multiple myeloma, managing multiple lines of treatment including BCMA-directed CAR T therapy, alongside a history of hypertension, respiratory infections, and type 2 diabetes, now receiving talquetamab.
